Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-27T00:47:34.268Z Has data issue: false hasContentIssue false
  • English
  • Français

Dosage and Administration Issues of Antipsychotic Agents (and Adjunctive Medicines) in the Acute Stabilization of Psychoses

Published online by Cambridge University Press:  07 November 2014

K. N. Roy Chengappa
Get access Rights & Permissions [Opens in a new window]

Abstract

There are several options and approaches available to practicing psychiatrists for the pharmacologic management of acute psychotic episodes that present in emergency room settings. This article focuses on the first hours and days of such episodes, the goals of treatment, and comparison of the “old favorites,” such as combination haloperidol and lorazepam (in liquid, tablet or injectable formulations), with the newer second-generation antipsychotic agents, such as olanzapine, ziprasidone, risperidone, quetiapine, or aripiprazole, which are available in different formulations. The speed of titration to an effective target dose for these newer agents are addressed as well.

Type
Academic Supplement
Information
CNS Spectrums , Volume 9 , Issue S9 , September 2004 , pp. 6 - 10
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Citrome, L, Volavka, J. Violent patients in the emergency setting. Psychiatr Clin North Am. 1999;22:769–801.CrossRefGoogle ScholarPubMed
2.Raftos, J. Treating the acutely psychotic patient. Aust Fam Physician. 2002;31:813–817.Google ScholarPubMed
3.Battaglia, J, Moss, S, Rush, J et al. , Haloperidol, lorazepam, or both for psychotic agitation? a multicenter, prospective, double-blind, emergency department setting. Am J Emerg Med. 1997;15:335–340Google Scholar
4.Bieniek, SA, Ownby, RI, Penalver, A et al. , A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapry. 1993;18:57–62.CrossRefGoogle Scholar
5.Garca-Trevino, ES, Hollister, LE, Overall, JE et al. , Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry. 1989;146:1598–1601.Google Scholar
6.Citrome, L. Atypical antipsychotics for acute agitation: new intramuscular options offer advantages. Postgrad Med. 2002;112:85–83, 94–96.CrossRefGoogle ScholarPubMed
7.Daniel, DG, Potkin, SG, Reeves, KR, Swift, RH, Harrigan, EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind randomized trial. Psychopharmacology. 2001;155(2):128–134.Google Scholar
8.Wright, P, Birkett, M, David, SR et al. , Double-blind, placebo-controlled comparison of intramuscular olanzapinc and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158(7):1149–1151.CrossRefGoogle ScholarPubMed
9.Meehan, K, Zhang, F, David, S et al. , A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21:389–397.CrossRefGoogle ScholarPubMed
10.Modell, S, Daniel, D, Stock, E et al. , Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. Int J Neuropsychopharmacol. 2004;7(Suppl 1):S416–S428.Google Scholar
11.Kinon, BJ, Hill, AL, Liu, H, Kollack-Walker, S. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacology. 2003;6(2):97–102.CrossRefGoogle ScholarPubMed
12.Currier, GW, Simpson, GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001;62:153–157.CrossRefGoogle ScholarPubMed
13.Baker, RW, Kinon, BJ, Maguire, GA, Liu, H, Hill, ALEffectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzpine in acute agitation. J Clin Psychopharmacol. 2003;23(4):342–348.CrossRefGoogle Scholar
14.Potkin, SG, Saha, AR, Kujawa, MJ et al. , Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia with schizoaffective disorder. Arch Gen Psychiatry. 2003;60(7):681–690.Google Scholar
15.Smith, MA, McCoy, R, Hamer, J, Brecher, M. Optimal titration for quetiapine: Pilot trial. Poster presented at: 42nd Annual Meeting of the New Clinical Drug Evaluation Unit; June 10–13, 2002; Boca Raton, Florida.Google Scholar
16.Chengappa, KNR, Goldstein, JM, Greenwood, M, John, V, Levine, J. A posthoc analyses of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clm Ther. 2003;25:530–541.CrossRefGoogle Scholar
17.Brecher, M, Huizar, K. Quetiapine vs. placebo for acute mania associated with bipolar disorder (STAMP 1). Poster presented at: 5th International Conference on Bipolar Disorder; June 12–14, 2003; Pittsburgh, Pennsylvania.Google Scholar
18.Jones, M, Huizar, K. Quetiapine monotherapy for mania associated with bipolar disorder. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1–6, 2004; New York, NY.Google Scholar
19.Sachs, G, Chengappa, KNR, Suppes, T et al. , Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2004;6:213–223.Google Scholar
20.Chengappa, KNR, Parepally, H, Brar, JS, Mullen, J, Shilling, A, Goldstein, JM. A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: A pilot study. Can J Psychiatry. 2003;48:187–194.CrossRefGoogle ScholarPubMed
21.Casey, DE, Daniel, DG, Wassef, AA, Tracy, KA, Wozniak, P, Sommervile, KW. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003;28:182–192.CrossRefGoogle ScholarPubMed